Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ce-326597. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR known ✓ | P32238 | 19/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ce-326597 SCHEMBL29556037 | 1.00 | CCKAR (1.00) | CCKARCCKBREP300CREBBP | |
| Ce-326597 SCHEMBL29454541 | 1.00 | CCKAR (1.00) | CCKARCCKBREP300CREBBP | |
| SCHEMBL5106792 | 0.92 | CCKAR (0.85) | CCKARCCKBREP300CREBBP | |
| SCHEMBL5099955 | 0.88 | CCKAR (0.79) | CCKARCCKBR | |
| SCHEMBL5103368 | 0.87 | CCKAR (0.77) | CCKARCCKBR | |
| SCHEMBL5103445 | 0.86 | CCKAR (0.76) | CCKARCCKBREP300CREBBP | |
| SCHEMBL5106860 | 0.86 | CCKAR (0.76) | CCKARCCKBREP300CREBBP | |
| SCHEMBL3347861 | 0.85 | CCKAR (0.73) | CCKARCCKBR | |
| SCHEMBL5107318 | 0.83 | CCKAR (0.70) | CCKARCCKBR | |
| SCHEMBL5099939 | 0.82 | CCKAR (0.70) | CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358242-B2 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC. (US) | 2008-04-15 | — | — | US | claimed |
| US-7265104-B2 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC. (US) | 2007-09-04 | — | — | US | claimed |
| EP-1753766-A1 | TETRAAZABENZO(E)AZULENE DERIVATIVES AND ANALOGS THEREOF | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005116034-A1 | TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050267100-A1 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC | 2005-12-01 | — | — | US | claimed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20250066337-A1 | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | PFIZER INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240140937-A1 | Diacylglycerol Acyl Transferase 2 Inhibitors | PFIZER INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20070265193-A1 | TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF | PFIZER INC | 2007-11-15 | — | — | US | disclosed |
| US-7265104-B2 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265104-B2 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265104-B2 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC. (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007079317-A2 | USE OF SEDATIVE HYPNOTICS FOR TREATING OBESITY OR MAINTAINING WEIGHT LOSS | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1753766-A1 | TETRAAZABENZO(E)AZULENE DERIVATIVES AND ANALOGS THEREOF | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116034-A1 | TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267100-A1 | Tetraazabenzo[e]azulene derivatives and analogs thereof | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, METTL3, RNASE1 | CCKAR 3274/4885CCKBR 4244/4885EP300 4307/4885 |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | CCKAR 1913/4885CCKBR 1770/4885EP300 75/4885 |
| US-20070265193-A1 | TETRAAZABENZO[E]AZULENE DERIVATIVES AND ANALOGS THEREOF | CCKAR, CCKBR, GLP1R | CCKAR 1/4885CCKBR 2/4885EP300 4563/4885 |
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | CCKAR 790/4885CCKBR 435/4885EP300 633/4885 |
| US-20250066337-A1 | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | DGAT2, ACAT2, DGAT1 | CCKAR 4431/4885CCKBR 4686/4885EP300 536/4885 |
| US-20050267100-A1 | Tetraazabenzo[e]azulene derivatives and analogs thereof | CCKAR, CCKBR, GPR119 | CCKAR 1/4885CCKBR 2/4885EP300 4179/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | CCKAR 110/4885CCKBR 344/4885EP300 1674/4885 |
| US-20240140937-A1 | Diacylglycerol Acyl Transferase 2 Inhibitors | DGAT2, DGAT1, LCLAT1 | CCKAR 4780/4885CCKBR 4766/4885EP300 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.